Last $67.91 USD
Change Today -0.14 / -0.21%
Volume 275.0K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:07 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

John M. Maraganore M.D., Ph.D.

Chief Executive Officer and Executive Director, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 169 board members in 7 different organizations across 10 different industries.

See Board Relationships
51$6,236,122
As of Fiscal Year 2013

Background*

Dr. John M. Maraganore, Ph.D., has been the Chief Executive Officer at Alnylam Pharmaceuticals Inc. since December 2002. Dr. Maraganore has been a Venture Partner at Third Rock Ventures, LLC since May 14, 2013. He joined the firm to participate in a limited capacity guiding strategy for it and its portfolio companies. Dr. Maraganore served as the President of Alnylam Pharmaceuticals Inc. from December 2002 to December 2007. From April 2000 to December 2002, he served ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

Director
Director
2002-Present
Chief Executive Officer and Executive Director
2006-2009
Former Director
2006-Present
Director and Member of Compensation Committee
2009-N/A
Former Director and Member of Compensation Committee
2010-N/A
Former Director
2011-Present
Director, Member of Audit Committee and Member of Compensation Committee
2012-Present
Director and Member of Compensation Committee

Education*

MS
The University of Chicago
PhD
The University of Chicago
BS
The University of Chicago

Other Affiliations*

Annual Compensation*

Salary$669,500
Total Annual Compensation$669,500

Stock Options*

All Other Compensation$7,596
Exercised Options191,612
Exercised Options Value$8,927,834
Exercisable Options1,281,255
Unexercisable Options375,000
Total Value of Options$8,927,834
Total Number of Options1,922,867

Total Compensation*

Total Annual Cash Compensation$1,108,924
Total Short Term Compensation$669,500
Other Long Term Compensation$7,596
Total Calculated Compensation$6,236,122
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $67.91 USD -0.14

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
George W. Hebard III, M.B.AInterim Principal Executive Officer, Interim Chief Operating Officer and Secretary
Enzon Pharmaceuticals Inc.
$428.5K
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
--
Mark J. Ahn Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
$737.0K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.